通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
以 oHSV 为基础的溶瘤病毒免疫疗法靶向癌症
英文原题：Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy.
查看英文原题
Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，癌症免疫疗法（如免疫检查点抑制剂（ICIs）、单克隆抗体（mAbs）、癌症疫苗和过继性细胞疗法（ACTs））的成功，彻底改变了传统的癌症治疗方式。然而，这些免疫治疗方式的疗效参差不齐，且许多疗法存在不良反应。溶瘤病毒免疫疗法（OViT）利用病毒直接或间接诱导抗癌免疫反应，正逐渐成为一种用于治疗不同类型癌症患者的新型免疫疗法。1型单纯疱疹病毒（HSV-1）具有许多使其成为有效OViT药物的特性，并且仍然是领先的候选者。其近期的临床成功促成了美国食品药品监督管理局（FDA）于2015年批准Talimogene laherparevec（T-VEC或Imlygic）用于治疗晚期黑色素瘤。在这篇综述中，我们讨论了基于溶瘤HSV-1的OViT开发的最新进展、其抗肿瘤作用机制以及近期临床试验的疗效数据。我们期望这些知识可用于指导未来oHSV在癌症治疗中的合理设计和应用。
展开英文摘要原文
The recent success of cancer immunotherapies, such as immune checkpoint inhibitor (ICIs), monoclonal antibodies (mAbs), cancer vaccines, and adoptive cellular therapies (ACTs), has revolutionized traditional cancer treatment.
However, these immunotherapeutic modalities have variable efficacies, and many of them exhibit adverse effects. Oncolytic viral Immunotherapy (OViT), whereby viruses are used to directly or indirectly induce anti-cancer immune responses, is emerging as a novel immunotherapy for treating patients with different types of cancer. The herpes simplex virus type-1 (HSV-1) possesses many characteristics that inform its use as an effective OViT agents and remains a leading candidate.
Its recent clinical success resulted in the Food and Drug Administration (FDA) approval of Talimogene laherparevec (T-VEC or Imlygic) in 2015 for the treatment of advanced melanoma. In this review, we discuss recent advances in the development of oncolytic HSV-1-based OViTs, their anti-tumor mechanism of action, and efficacy data from recent clinical trials.
We envision this knowledge may be used to inform the rational design and application of future oHSV in cancer treatment.
论文信息
- 作者
- Nasar RT、Uche IK、Kousoulas KG
- 第一作者单位
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.United States
- 通讯作者单位
- Division of Biotechnology and Molecular Medicine, Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.United States
- 文献类型
- 综述
- 期刊
- Current issues in molecular biology2024 Jun 3
- 原文标识
- PubMed 38921005 · DOI 10.3390/cimb46060334
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →